Abstract:Mesenchymal stem cell (MSC)-based biomimetic delivery has been actively explored for drug accumulation and penetration into tumors by taking advantage of the tumor-tropic and penetration properties of MSCs. In this work, we further demonstrated the feasibility of MSC-mediated nano drug delivery, which was characterized by the "Trojan horse"-like transport via an endocytosis-exocytosis-endocytosis process between MSCs and cancer cells. Chlorin e6 (Ce6)-conjugated polydopamine nanoparticles (PDA-Ce6) were developed and loaded into the MSCs. Phototherapeutic agents are safe to the MSCs, and their very low dark toxicity causes no impairment of the inherent properties of MSCs, including tumor-homing ability. The MSCs loaded with PDA-Ce6 (MSC-PDA-Ce6) were able to target and penetrate into tumors and exocytose 60% of the payloads in 72 h. The released PDA-Ce6 NPs could penetrate deep and be re-endocytosed by the cancer cells. MSC-PDA-Ce6 tended to accumulate in the lungs and delivered PDA-Ce6 into the tumors after intravenous injection in the mouse model with lung melanoma metastasis. Phototoxicity can be selectively triggered in the tumors by sequentially treating with near-infrared irradiation to induce photodynamic therapy (PDT) and photothermal therapy (PTT). The MSC-based biomimetic delivery of PDA-Ce6 nanoparticles is a potential method for dual phototherapy against lung melanoma metastasis.

Correction: A Trojan Horse Biomimetic Delivery Strategy Using Mesenchymal Stem Cells for PDT/PTT Therapy Against Lung Melanoma Metastasis

A Trojan horse biomimetic delivery strategy using mesenchymal stem cells for PDT/PTT therapy against lung melanoma metastasis (vol 17, pg 2431, 2020))

Erratum: Targeting NF-κB/AP-2β Signaling to Enhance Antitumor Activity of Cisplatin by Melatonin in Hepatocellular Carcinoma Cells.

Supporting Information Trojan-Horse Biomimetic Delivery Strategy using Mesenchymal Stem Cells for PDT/PTT Therapy Against Lung Melanoma Metastasis

A Trojan Horse Biomimetic Delivery Strategy Using Mesenchymal Stem Cells for PDT/PTT Therapy Against Lung Melanoma Metastasis

Correction: MnO 2 /Ce6 microbubble-mediated hypoxia modulation for enhancing sono-photodynamic therapy against triple negative breast cancer

Correction: Highly Penetrative Liposome Nanomedicine Generated by a Biomimetic Strategy for Enhanced Cancer Chemotherapy.

Correction: Tumor-targeting, enzyme-activated nanoparticles for simultaneous cancer diagnosis and photodynamic therapy

Correction: Near-infrared light triggered photothermal therapy and enhanced photodynamic therapy with a tumor-targeting hydrogen peroxide shuttle

Correction: Near-infrared light triggered photothermal and photodynamic therapy with an oxygen-shuttle endoperoxide of anthracene against tumor hypoxia

Correction To: BM-MSC-derived Exosomes Alleviate Radiation-Induced Bone Loss by Restoring the Function of Recipient BM-MSCs and Activating Wnt/β-catenin Signaling

Correction: an Oxygen Self-Sufficient NIR-responsive Nanosystem for Enhanced PDT and Chemotherapy Against Hypoxic Tumors

Correction: Co-delivery of anionic epitope/CpG vaccine and IDO inhibitor by self-assembled cationic liposomes for combination melanoma immunotherapy

Correction: The improved targeting of an aspirin prodrug albumin-based nanosystem for visualizing and inhibiting lung metastasis of breast cancer

Erratum: Porphyrin-grafted Lipid Microbubbles for the Enhanced Efficacy of Photodynamic Therapy in Prostate Cancer through Ultrasound-controlled In Situ Accumulation: Erratum

Correction: Ce6-Conjugated and Polydopamine-Coated Gold Nanostars with Enhanced Photoacoustic Imaging and Photothermal/photodynamic Therapy to Inhibit Lung Metastasis of Breast Cancer.

Codelivery of Doxorubicin and MDR1-siRNA by Mesoporous Silica Nanoparticles-Polymerpolyethylenimine to Improve Oral Squamous Carcinoma Treatment [Corrigendum]

Correction: A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy

Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1

Correction: Combining PD-L1 inhibitors with immunogenic cell death triggered by chemo-photothermal therapy via a thermosensitive liposome system to stimulate tumor-specific immunological response

Erratum to: Antimetastatic activity of MONCPT in preclinical melanoma mice model